Exicure Inc. (NASDAQ:XCUR) agreed to sell its GPC-100 program assets to South Korea-based GPCRT Inc. for an aggregate cash price of 6.5 billion South Korean won (approximately $4.8 million).
The transaction aligns with the company’s ongoing evaluation of strategic alternatives designed to maximize stockholder value and strengthen its overall financial position.
Exicure and its wholly owned subsidiary, GPCR Therapeutics USA Inc., executed the Intellectual Property, Asset and License Assignment Agreement with GPCRT on November 4, 2026.
Divestiture Of GPC-100 Program Rights
The asset transfer encompasses the company’s rights under a License and Collaboration Agreement dated January 19, 2025, with GPCR Therapeutics, Inc.
In addition to those licensing rights, GPCRT acquires related program contracts, intellectual property, clinical and regulatory records, materials, and equipment used by Exicure and GPCR Therapeutics USA.
GPC-100, also known as burixafor, is undergoing clinical evaluation alongside propranolol to facilitate stem cell mobilization in patients with multiple myeloma.
GPCR Therapeutics USA concluded a Phase 2 clinical trial evaluating the combination in January 2026. Following the transaction’s closing, GPCR Therapeutics USA will remain a wholly owned operating subsidiary of Exicure.
Staged Payment Structure And Financial Terms
The agreement establishes a staged payment structure for the 6.5 billion won total consideration. GPCRT previously remitted 500 million won, which the parties will credit directly against the total purchase price.
GPCRT must deliver an additional installment of 2.0 billion won on or before November 16, 2026.
The buyer will pay the remaining 4 billion won balance upon formal closing of the transaction, unless both parties agree in writing to an alternative payment date.
Reallocation Of Liabilities And Future Costs
Following the closing, GPCRT will assume all contractual responsibilities under the assigned program agreements, including future milestone and royalty obligations.
The buyer will also absorb all operating costs that the GPC-100 program incurs on or after Sept. 1, 2026.
In contrast, Exicure and GPCR Therapeutics USA will retain all other liabilities, including any program-related liabilities incurred prior to the September 1 cutoff date.
XCUR Price Action: Exicure shares were down 7.41% at $1.00 during premarket trading on Wednesday. The stock is trading near its 52-week low of $0.77, according to Benzinga Pro data.
Image via Shutterstock